Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study by Alix Arnaud MS, Samantha Schilsky PhD, MPH, Jackie Lucia BS, Marta Maia MS, Fernando Laredo MS, Ana Paula Marques MD, Hikaru Okada MD, PhD, Andrew W. Roberts PharmD, PhD

Get full text